CASI Pharmaceuticals, Inc. CASI
0.15 USD 0.00 (+0.00%)
Mar 17, 2026, 9:30 AM EDT
0.15 Day range 0.1505
52-week range unavailable
- YTD
- -82.29%
- 1 year
- -92.24%
News
defenseworld.net Contrasting CASI Pharmaceuticals (NASDAQ:CASI) and Organon & Co. (NYSE:OGN) Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies…
defenseworld.net CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
accessnewswire.com CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal…
defenseworld.net Siga Technologies (NASDAQ:SIGA) and CASI Pharmaceuticals (NASDAQ:CASI) Financial Comparison CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Siga Technologies (NASDAQ: SIGA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast…
feeds.benzinga.com What Drove CASI Pharmaceuticals' 24% Rise After Hours? CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Nasdaq Gains Over 1%; TJX Posts Upbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Dow Jumps 200 Points; Lowe's Issues Weak Earnings Outlook 
accessnewswire.com CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
accessnewswire.com CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
accessnewswire.com CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia Additional proof of concept data consistent and strengthen data set shared at ASH 2025 Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA /…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
accessnewswire.com CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential…
accessnewswire.com CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc.…
accessnewswire.com CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially…
accessnewswire.com CASI Pharmaceuticals Announces Changes in Board Governance James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a…
accessnewswire.com CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential…
accessnewswire.com CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential…
accessnewswire.com CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential…
accessnewswire.com CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting - CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire /…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
accessnewswire.com CASI Pharmaceuticals Appoints James Huang to Board of Directors - Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb)…
accessnewswire.com CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for…
accessnewswire.com CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors - Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations -…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Earnings Scheduled For November 14, 2024
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Market-Moving News for June 27th CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
- benzinga.com This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
- benzinga.com Earnings Scheduled For August 12, 2022 Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.
- benzinga.com Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
benzinga.com Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday.- benzinga.com 24 Stocks Moving in Tuesday's Pre-Market Session Gainers Valneva SE (NASDAQ: VALN) shares rose 83.6% to $25.18 in pre-market trading following Pfizer agreement to acquire an 8.1% stake.
- benzinga.com 62 Biggest Movers From Yesterday Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.
- benzinga.com 70 Biggest Movers From Friday Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for…